Corporate action, page-32

As a major shareholder for many many years our resolve has been really tested but our faith in the science has kept us here.

The sudden resignation of Michael without much clarification or reassurances from the current BoD is just another disappointment and seemingly disregard for us shareholders.

We have seen the highs and lows leading up to and following the canine trials and Elanco's disinterest, the loss of our CSO, Dr Richard Mollard and Colin La Galia and then the sudden shutdown of Epichem all with no real explanation.

The last 7 or so months since Michael Thurn came on board, the company has become more invigorated, communications has improved and confidence instilled so much so we converted over 1.2 million options in support of the company and the anticipated results with the MND trials.

So yes, we are fully on board in trying to sway Michael Thurn to continue in his role as CEO and he has our full support.

Denise